Refractory Migraine
7
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine
EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization
Localized Injection of Lidocaine Via the Middle Meningeal Artery for Intractable Headache Treatment
Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1
Occipital Nerve Stimulation in Chronic Migraine
Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches
Pulsed Electromagnetic Field Therapy in the Refractory Migraine